Cytogenetic and FISH techniques in myeloid malignancies.

Chromosome analysis is an essential part of the diagnostic testing of myeloid malignancies. Good chromosome preparations are essential for a complete cytogenetic analysis. This means plentiful metaphase spreads with well-spread crisply banded chromosomes. To achieve such a result, several variables, including the growth rate of the leukemic cells, are critical. The method described in this chapter has been extensively tested and should produce reasonable results from most cases. Fluorescence in situ hybridization (FISH) is less influenced by sample variation and as a result may be obtained from either metaphase spreads or interphase cells. Moreover, FISH is capable of describing chromosome rearrangements at the gene level, rather than at the gross level shown by conventional cytogenetics. It does not, however, provide information on genetic rearrangements other than at the specific target site of the probe used, unlike conventional cytogenetics. Thus, these two techniques complement each other and are both now essential elements of chromosome analysis.

[1]  G. Vance,et al.  Proficiency testing for laboratories performing fluorescence in situ hybridization with chromosome-specific DNA probes. , 2002, Archives of pathology & laboratory medicine.

[2]  O. Garson,et al.  Fluorodeoxyuridine synchronization of bone marrow cultures. , 1983, Cancer genetics and cytogenetics.

[3]  S. Fröhling,et al.  Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Fröhling,et al.  Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Melo,et al.  Chronic myeloid leukemia--advances in biology and new approaches to treatment. , 2003, The New England journal of medicine.

[6]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .

[7]  M. Leversha,et al.  Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. , 2000, Blood.

[8]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[9]  D. Pinkel,et al.  Introduction to fluorescence in situ hybridization : principles and clinical applications , 1999 .

[10]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[11]  N. Jones Human Cytogenetics: Malignancy and Acquired Abnormalities, Third Edition, A Practical Approach , 2002, Chromosome Research.